[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-330723-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-330723-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-regulated-oncolytic-adenovirus-carrying-ercc1-sirna-gene-possesses-potent-antitumor-effect-on-ovarian-cancer-cells","Dual-regulated oncolytic adenovirus carrying ERCC1-siRNA gene possesses potent antitumor effect on ovarian cancer cells","","Ovarian cancer is a multifactorial, lethal disease with rising incidence and poorly understood molecular drivers of invasiveness, metastasis, and drug resistance. Oncolytic viruses delivering therapeutic transgenes offer an alternative to chemotherapy, which is limited by innate and acquired resistance. This study engineered Ad-siERCC1, a dual-regulated oncolytic adenovirus expressing ERCC1 siRNA controlled by hTERT and HIF promoters. Ad-siERCC1 suppresses proliferation, migration, and invasion while downregulating ERCC1 to improve cisplatin sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-regulated-oncolytic-adenovirus-carrying-ercc1-sirna-gene-possesses-potent-antitumor-effect-on-ovarian-cancer-cells/330723/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-regulated-oncolytic-adenovirus-carrying-ercc1-sirna-gene-possesses-potent-antitumor-effect-on-ovarian-cancer-cells/330723.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is Ad-siERCC1 and how is it regulated?","Question",{"text":63,"@type":64},"Ad-siERCC1 is an oncolytic adenovirus carrying ERCC1 short interfering RNA. It is regulated by hTERT and HIF promoters.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Ad-siERCC1 affect ovarian cancer cell behavior?",{"text":68,"@type":64},"Ad-siERCC1 inhibits proliferation, migration, and invasion of ovarian cancer cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How does ERCC1 siRNA relate to cisplatin resistance?",{"text":72,"@type":64},"Downregulation of ERCC1 by siRNA ameliorates drug resistance to cisplatin chemotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},330723,1790143692,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Molecular Medicine rePorTS 30: 120, 2024  \nDual‑regulated oncolytic adenovirus carrying ERCC1‑siRNA gene possesses potent antitumor effect on ovarian cancer cells  \n* *  \nTING ZHAO , Wei Ye , RUI ZHANG, XIAOYAN ZHU, QIN SHI, XIAOFENG XU, WEIFENG CHEN, LING XU and YAPING MENG  \nDepartment of Obstetrics and Gynecology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China  \nReceived November 29, 2023; Accepted March 18, 2024  \nDOI: 10. 3892/mmr.2024.13245  \nAbstract. ovarian cancer is a multifactorial and deadly disease. Despite significant advancements in ovarian cancer therapy, its incidence is on the rise and the molecular mechanisms underlying ovarian cancer invasiveness, metastasis and drug resistance remain largely elusive, resulting in poor prognosis. Oncolytic viruses armed with therapeutic transgenes of interest offer an attractive alternative to chemical drugs, which often face innate and acquired drug resistance. The present study constructed a novel oncolytic adenovirus carrying ERCC1 short interfering (si)rna, regulated by hTERT and HIF promoters, termed Ad‑siERCC1. The findings demonstrated that this onco‑ lytic adenovirus effectively inhibits the proliferation, migration and invasion of ovarian cancer cells. Furthermore, the down‑ regulation of ERCC1 expression by sirna ameliorates drug resistance to cisplatin (DDP) chemotherapy. It was found that Ad‑siERCC1 blocks the cell cycle in the G1 phase and enhances apoptosis through the PI3K/AKT‑caspase‑3 signaling pathways in SKOV3 cells. The results of the present study highlighted the critical effect of oncolytic virus Ad‑siERCC1 in inhibiting the survival of ovarian cancer cells and increasing chemotherapy sensitivity to DDP. These findings underscore the potent anti‑ tumor effect of ad‑siercc1 on ovarian cancers in vivo.  \nIntroduction  \nOvarian cancer is one of the most common malignant tumors affecting female reproductive organs worldwide and it has  \nCorrespondence to: Dr Yaping Meng or Dr Ling Xu, Department of Obstetrics and Gynecology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, 1 Chengbei Road, Shanghai 201800, P.R. China  \ne‑mail: [ypingfly@126.com](ypingfly@126.com)  \nE‑mail: [xuling19813@126.com](xuling19813@126.com)  \n*contributed equally  \nKey words: ERCC1, hTERT/HIF, adenovirus, proliferation, ovarian cancer  \nthe highest mortality rate among gynecological tumors (1,2) . Due to the lack of early diagnostic methods and inconspicuous clinical symptoms, most women are diagnosed at an advanced stage (corresponding to stages III and IV), resulting in 5‑year survival rates ranging from 26‑42%(3,4) . despite signifi‑ cant advancements in medical science and technology, the combination of surgery and chemotherapy has improved the therapeutic outcomes for ovarian cancer in recent years, but unfortunately, there has been no significant improvement in the 5‑year survival rate (5) . Therefore, it is imperative to explore new strategies to enhance the treatment of ovarian cancer.  \nThe current front‑line standard of care for ovarian cancer involves surgery followed by platinum‑taxane maintenance chemotherapy (6,7) . However, chemotherapy resistance remains a significant factor contributing to the high mortality rate in ovarian cancer (5) . Various factors, such as decreased drug accumulation, elevated glutathione levels, increased metallothionein and enhanced DNA repair ability, have been implicated in the development of tumor cell resistance topaclitaxel or platinum. Among these factors, the most crucial one is the enhanced tolerance and repair of DNA damage through the nucleotide‑excision‑repair (NER) pathway (8,9) . The NER pathway is highly conserved and represents one of the major DNA repair mechanisms in mammalian cells that counteract the formation of genetic damage (8). Understanding the involvement of the NER pathway in chemotherapy ","cbCaihzIyLBH8cl2","https://ap.wps.com/l/cbCaihzIyLBH8cl2","pdf",6754441,11,"English","# Abstract\n# Introduction\n## ERCC1 and platinum resistance\n## Oncolytic adenovirus vectors","[{\"question\":\"What is Ad-siERCC1 and how is it regulated?\",\"answer\":\"Ad-siERCC1 is an oncolytic adenovirus carrying ERCC1 short interfering RNA. It is regulated by hTERT and HIF promoters.\"},{\"question\":\"How does Ad-siERCC1 affect ovarian cancer cell behavior?\",\"answer\":\"Ad-siERCC1 inhibits proliferation, migration, and invasion of ovarian cancer cells.\"},{\"question\":\"How does ERCC1 siRNA relate to cisplatin resistance?\",\"answer\":\"Downregulation of ERCC1 by siRNA ameliorates drug resistance to cisplatin chemotherapy.\"}]","Dual-regulated oncolytic adenovirus carrying ERCC1-siRNA gene possesses potent antitumor effect on ovarian cancer cells | PDF",1789989851,28]